To address this limitation, we plan to evaluate our models on clinically-relevant breast cancer cells other than MCF-7 cells (ER + breast cancer), such as the BT-474 (ER + HER2+ breast cancer) and MD-MBA-231 (triple-negative breast cancer) considered by Howard et al. (2022). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.